Fiche du document
2014
- handle: 10670/1.1h3vwm
- issn: 1389-2002
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/25658128
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1875-5453
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_7E7363931E000
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Citer ce document
M. Cozzolino et al., « Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide. », Serveur académique Lausannois, ID : 10670/1.1h3vwm
Métriques
Partage / Export
Résumé
Sucroferric oxyhydroxide (VELPHORO(®)) is a polynuclear iron-based phosphate binder recently approved for the treatment of hyperphosphataemia in patients with chronic kidney disease (CKD). As a number of the available phosphate binders do not provide the optimal combination of good efficacy, adequate tolerability and low pill burden, sucroferric oxyhydroxide constitutes a promising alternative. Among the attributes of an ideal phosphate binder is minimal absorption and, hence, low risk of systemic toxicity. Accordingly, the iron-releasing properties and absorption, distribution, metabolism and excretion (ADME) profile of sucroferric oxyhydroxide, as well as the possibility of iron accumulation and toxicity, were investigated in a series of preclinical studies. The effect of sucroferric oxyhydroxide on the progression of vascular calcification was also investigated. Sucroferric oxyhydroxide exhibited a high phosphate-binding capacity and low iron-releasing properties across the physiological pH range found in the gastrointestinal tract. In the ADME studies, uptake of (59)Fe-radiolabelled sucroferric oxyhydroxide was low in rats and dogs (